Article Information
PubMed
Published By
History
- Received May 19, 2004
- Revision received August 3, 2004
- Accepted August 3, 2004
- First published October 13, 2004.
- Version of record published October 13, 2004.
Copyright & Usage
Copyright © 2004 Society for Neuroscience 0270-6474/04/249117-10.00/0
Author Information
- David E. Sleat1,2,
- Jennifer A. Wiseman1,
- Mukarram El-Banna1,
- Kwi-Hye Kim1,
- Qinwen Mao4,
- Sandy Price1,
- Shannon L. Macauley5,
- Richard L. Sidman6,
- Michael M. Shen1,3,
- Qi Zhao5,
- Marco A. Passini5,
- Beverly L. Davidson4,
- Gregory R. Stewart5, and
- Peter Lobel1,2
- 1Center for Advanced Biotechnology and Medicine, and Departments of 2Pharmacology and 3Pediatrics, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, 4Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, 5Genzyme Corporation, Framingham, Massachusetts 01701, and 6Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115
Author contributions
Disclosures
- Received May 19, 2004.
- Revision received August 3, 2004.
- Accepted August 3, 2004.
This work was supported by National Institutes of Health Grants NS37918 (P.L.) and HD42837 (M.M.S.). We thank Rosalie Gin, Vivienne Halili, Holly Collins, Jie Bu, and Tatyana Taksir for technical assistance and Istvan Sohar, Li Lin, Thomas Ludwig, John Pintar, Alwin Schuller, and Jixiang Ding for helpful discussions, reagents, and other assistance.
Correspondence should be addressed to Peter Lobel or David Sleat, Center for Advanced Biotechnology and Medicine, 679 Hoes Lane, Piscataway, NJ 08854. E-mail: lobel{at}cabm.rutgers.edu or sleat{at}cabm.rutgers.edu.
G. R. Stewart's present address: Medtronic Neurological, Columbia Heights, MN 55421.
Copyright © 2004 Society for Neuroscience 0270-6474/04/249117-10$15.00/0
Statistics from Altmetric.com
Article usage
In this issue
A Mouse Model of Classical Late-Infantile Neuronal Ceroid Lipofuscinosis Based on Targeted Disruption of the CLN2 Gene Results in a Loss of Tripeptidyl-Peptidase I Activity and Progressive Neurodegeneration
